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Mitochondrial respiratory chainSUCLA2-related mitochondrial DNA (mtDNA) depletion syndrome is a result of mutations in the β subunit of
the ADP-dependent isoform of the Krebs cycle succinyl-CoA synthase (SCS). The mechanism of tissue
speciﬁcity and mtDNA depletion is elusive but complementation by the GDP-dependent isoform encoded by
SUCLG2, and the association with mitochondrial nucleoside diphosphate kinase (NDPK), is a plausible link.
We have investigated this relationship by studying SUCLA2 deﬁcient ﬁbroblasts derived from patients and
detected normal mtDNA content and normal NDPK activity. However, knockdown of SUCLG2 by shRNA in
both patient and control ﬁbroblasts resulted in a signiﬁcant decrease in mtDNA amount, decreased NDPK and
cytochrome c oxidase activities, and a marked growth impairment. This suggests that, SUCLG2, to a higher
degree than SUCLA2, is crucial for mtDNA maintenance and that mitochondrial NDPK is involved. Although
results pertain to a cell culture system, the ﬁndings might explain the pathomechanism and tissue speciﬁcity
in mtDNA depletion caused by defective SUCLA2.Metabolic Diseases, Hadassah-
erusalem, Israel. Tel.: +972 2
lsebet.ostergaard@dadlnet.dk
i.ac.il (A. Saada).
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Mitochondrial DNA depletion syndromes (MDS) are a genetically
heterogeneous group of autosomal recessive disorders characterized by
decreased mtDNA content with accompanying reduction of the
activities of mitochondrial respiratory chain (RC) complexes I, III, IV,
and V. MDS usually present in infancy or childhood in a tissue speciﬁc
manner mainly affects brain and muscle [1,2]. SUCLA2-related
mitochondrial MDS (MIM ID#612073) is a result of mutations in the
SUCLA2 gene encoding the β subunit of the ADP-dependent isoform of
succinyl-CoA synthase (SCS) (EC 6.2.1.5) [3]. SCS is a mitochondrial
matrix enzyme that catalyzes the reversible synthesis of succinyl-CoA
from succinate and CoA. The reverse reaction occurs in the Krebs cycle,
while the forward reaction may produce succinyl-CoA for activation of
ketone bodies and heme synthesis. SCS is composed of an invariant α
subunit encoded by SUCLG1 and a β subunit that determines the
enzyme's nucleotide speciﬁcity. The GTP-speciﬁc β subunit encoded by
SUCLG2 is a component of the second SCS isoform (EC 6.2.1.4) which
catalyzes GDP dependent reactions [4].
Deﬁciency of SUCLA2 results in Leigh's or a Leigh-like syndromewith
onset of severe hypotonia in early infancy, severemuscular atrophy, andsensorineural hearing impairment. Most patients die in childhood. The
metabolic ﬁndings usually show urinary excretion of methylmalonic
acid (MMA), elevated plasma methylmalonic acid concentration, and
elevated plasma lactate concentration [5–7].
SUCLG1 deﬁciency can be more severe than SUCLA2 deﬁciency,
causing MDS with fatal, infantile lactic acidosis (MIM ID#245400)
[1,3], but a phenotype indistinguishable from that of patients with
SUCLA2 deﬁciency has also been described [8,9].
The pathomechanismof SCS deﬁciency remains elusive as there is no
obvious connection between a Krebs cycle enzyme and mtDNA
metabolism. A plausible link might be the possible association between
the mitochondrial form of nucleoside diphosphate kinase (NDPK)
(NM23-H4, NME4) and SCS [10–12].
Wehave investigated this association by studying normalﬁbroblasts
and SUCLA2 deﬁcient ﬁbroblasts derived from patients, showing that
knockdown of SUCLG2 results in a decreased mtDNA content, COX
activity, and mitochondrial NDPK activity.
2. Materials and methods
2.1. Tissue culture
Primary ﬁbroblasts (from forearm biopsies, taken with informed
consent, approved by the local IRB) were obtained from three patients.
Patient ELN harbored a complex genomic rearrangement in the SUCLA2
gene, with a homozygous deletion of 43 nt, encompassing the last 14 nt
of exon 6 and the ﬁrst 29 nt of IVS6, and an insertion of 5 nt
(32720del43ins5). This mutation was reported to result in the skipping
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the SUCLA2 gene (534+1 GNA), which is reported to result in the
skipping of exon 4 [6]. In patient AK, a deletion of the whole gene was
found. None of the exons could be ampliﬁed by PCR, and a homozygous
deletion of the gene was conﬁrmed by quantitative PCR of the ﬁrst and
last exons.
The cells were cultured in DMEM medium containing 4.5 g glucose
per liter and supplemented with 10% fetal calf serum, 50 μg/μl uridine,
and 110 μg/ml pyruvate (permissive growth medium). For growth
assessment, 12×103 cells were seeded in triplicates on 24 well plates.
The following day, the mediumwas changed to the usual medium or to
glucose-free RPMI supplementedwith 10% dialyzed fetal calf serumand
5 mMgalactose (GALmedium). After 72 h, viable cells were counted by
trypan blue exclusion. All other measurements were performed in cells
obtained from conﬂuent tissue cultures. (All reagents for tissue culture
were from Biological Industries, Kibbutz Beit Haemek, Israel).2.2. shRNA interference
A mixture of MISSION® shRNA plasmid DNA vector targeted
against SUCLG2 or a nontarget shRNA control vector (Sigma-Aldrich)
were introduced into 293FT cells by cotransfection with pLP1, pLP2,
and pLP/VSVG plasmids using lipofectamine according to the
manufacturer's instructions (ViraPower; Invitrogen, California, USA).
The virus-containing supernatants were harvested, ﬁltered, and target
cells were infected with virus supernatant containing polybrene.
Stably transfected cells were obtained by selection with puromycin
(4 mg/ml).2.3. mRNA transcript analysis
RT–PCR was performed in order to study the effect of SUCLA2
mutations on exon skipping and to show down regulation of SUCLG2
following shRNA.
Total RNA from ﬁbroblasts was prepared using TRI reagent (Sigma-
Aldrich) and equal amounts were reverse transcribed using ImProm-II
(Promega, Wisconsin, USA) reverse transcriptase kit with a hexamer
mixture as the template primer. PCR (SUCLA2, SUCLG2, andβ-actin)was
performed on cDNA samples using the following primers:
SUCLA2 forward—5′-TGTCGTGATAAAGGCACAGG-3′
SUCLA2 reverse—5′-CTTTTGGCGATAGGCTGAAT-3′
SUCLG2 forward—5′-CCCTAATGTTGTGGGACAGC-3′
SUCLG2 reverse—5′-GGAATTCTGCGTTGTCATCA-3′
β-actin served as an intrinsic control for SUCLG2 using the following
primers:
forward—5′-CGAGGCCCCCCTGAAC-3′
reverse—5′-TCTCAAACATGATCTGGGTCATCT-3′
An approximate estimation of the reduction SUCLG2 transcripts
inducedby shRNAwasobtainedbydigital imagingwithTINA2 software.Fig. 1. Analysis of SUCLA2 and SUCLG2mRNA. Total RNA from control and patient (AK, RJ,
ELN) cells, untreated (top), treatedwith SUCLG2 shRNA (sh), or control vector shRNA (cv)
(middle). RNA was reverse transcribed to cDNA and subjected to PCR using speciﬁc
primers to SUCLA2 or SUCLG2.β-actin served as an intrinsic control (bottom). Sizemarkers
were run in the ﬂanking slots.2.4. mtDNA quantiﬁcation
Total mtDNAwas quantiﬁed by real-time PCR essentially as described
[13]. Theprimerpair formtDNAwas5′-GTACCCACGTAAAGACGTTAGG-3′
and 5′-TACTGCTAAATCCACCTTCG-3′. The ﬂuorescent probe CCCAT-
GAGGTGGCAAGAAAT was labeled at the 5′-end with the reporter dye
VIC and at the 3′-end with the quencher dye TAMRA. RNAseP served as a
nuclear DNA control. Cycling and ﬂuorescence measurements were
performed by an ABI PRISM 7700 Sequence Detection System (Applied
Biosystems, USA).2.5. Mitochondrial preparation and enzymatic analyses
Mitoplasts were prepared from ca. 4×106 cells by homogenization,
centrifugation, and digitonin treatment [14]. Enzymatic activity of
cytochrome c oxidase (COX) was measured by following the oxidation
of 50 μM reduced cytochrome c at 550 nm in 10 mM potassium
phosphate buffer pH 7.0 at 37 °C.
NDPKactivitywas assayedwith 10 μM
3
H-TDP as the labeled substrate
in 20 mM Tris/HCl, pH 7.6, 3 mM DTT, 1 mM MgCl2, and 0.2 mM ATP.
Reaction was started by addition of extracts/enzyme, incubated at 37 °C
for 3 min, and stopped by addition of EDTA and kept on ice. Tenmicroliter
of reactionmixturewas applied toTLC (PEI Cellulose,Merck). The reaction
products were then separated by 0.2 M NaH2PO4. Non-radioactive
nucleotides were used as markers. The products were cut out, eluted,
mixed with scintillation ﬂuid, and counted. The
3
H-TDP, used for NDPK
activity measurements, was synthesized enzymatically from
3
H-dThd
(methyl-
3
H-thymdine; PerkinElmer) using Uu-TK and Ba-TMPK and
puriﬁed [15,16].
The enzymatic activities were normalized to citrate synthase (CS), a
mitochondrial control enzyme which was measured spectrophotometri-
cally as described [17].
2.6. Immunocytochemistry
Fibroblasts grown on ﬁbronectin-coated coverslips were incubated
with MitoTracker Red CM-H2XRos (Molecular Probes, Eugene, Oregon,
USA),ﬁxedwith4%paraformaldehyde, permeabilizedwith0.25%Triton
X-100, incubated with primary antibodies directed against TFAM
(a generous gift from Dr. Manuel Rojo, Bordeaux, France), detected
with FITC conjugated secondary antibodies (Jackson ImmunoResearch
Laboratories, West Grove, PA, USA), and visualized by confocal
microscopy (10×40). For measuring DNA synthesis, ﬁbroblasts were
grown for 24 h in the presence of 15 μM 5-bromo-2-deoxyuridine
(BrdU; MP Biomedicals, Solon, OH, USA) in rich growth medium but
without uridine, prior to MitoTracker staining and ﬁxation. The cells
were permeabilized with Triton X-100 and the antigen was exposed by
2 M HCl and detected by mouse-anti BrdU (AbD Serotec, Oxford, UK)
and FITC conjugated secondary antibodies. (Jackson ImmunoResearch
Laboratories, West Grove, PA, USA).
3. Results
The disruption of SUCLA2mRNA in the patient cells was shown by
RT–PCR (Fig. 1 top). Control ﬁbroblasts showed the expected 567 bp
fragment including exons 3–6 and part of 7 while the patient samples
ELN and RJ disclosed shorter RT–PCR products, corresponding to the
Fig. 2. Enzymatic activity of NDPK and COX, cell growth, and mtDNA content in cells treated with SUCLG2 shRNA. Fibroblasts from controls (n=2) and patients (AK, RJ, ELN) were
stably transfected with shRNA against SUCLG2 (SUCLG2sh) or a control vector (cv). mtDNA/nDNA ratios are presented as percentage relative to controls transformed with the control
vector (A). Enzymatic activities of COX (B) and NDPK (C) in isolated mitoplasts are presented as the ratio to CS. Growth was assessed in rich growth medium and glucose free
medium (GAL) by counting viable cells (D). Results are presented as mean±SD from duplicate samples, performed on at least two separate occasions.
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presence of truncated transcripts. Patient sample AK did not display
any detectable message as expected (Fig. 1 top).
Semi quantitative analysis by RT–PCR of the reduction of SUCLG2
mRNA, induced by shRNA treatment, disclosed a signiﬁcant 95% decreaseFig. 3. Immunocytochemistry of BrdU incorporation and TFAM in cells treated with SUCLG2
against SUCLG2 (SUCLG2sh) or a control vector (cv). The upper panel contains cells incubate
(green). The lower panel contains cells incubated with MitoTracker (red) and subsequently
detected by confocal ﬂuorescence microscopy.in two controls (one is depicted in Fig. 1 middle) and partial decreases,
85%, 60%, and 40%, in AK, RJ, and ELN, respectively. Cells treatedwith non-
target control shRNAdisplayednormal transcript amounts (Fig. 1middle).
ThemtDNA/nDNA ratioswerewithin the normal range in all patient
cells (Fig. 2A). The COX activity was near normal in ELN, slightlyshRNA. Fibroblasts from control and patient ELN were stably transfected with shRNA
d with BrdU and MitoTracker (red) and subsequently stained with anti-BrdU antibodies
stained with anti-TFAM antibodies (green). The ﬁgure depicts the overlay (yellow) as
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activities were not statistically different from the controls (Fig. 2C).
Growthof ELNandRJwasmore severely impairedon glucose freemedia
(41% and 64% of normal growth rates, respectively) relative to controls
(71% of normal growth rates), while growth of AK was slow in both
media.
All SUCLG2 shRNA treated cells, including controls, displayed a
notable, 34%–56% decrease in mtDNA/nDNA ratio compared to their
respective control vector treated cells (Fig. 2A). COX activity was also
relatively decreased in controls and in ELN (25%), whereas a less
signiﬁcant decrease in cells with an a priori lower COX activity was
found (Fig. 2B). A considerable (45%–60%) decrease in NDPK activity
was observed in all SUCLG2 shRNA treated cells (Fig. 2C).
Growth on GAL medium was severely affected not only in SUCLG2
shRNA treated patient cells but also in control cells (32% growth)
compared to cells treated with control vector. The decrease in control
cell growth was comparable to that of RJ and ELN (41% and 13%,
respectively). AK cells did not display any growth but rather detached
and the ﬁnal cell count was less than the initial number seeded.
Generally, the growth of shRNA treated cells in rich medium was
impaired but lessmarkedly than inGAL (Fig. 2C). These cells also quickly
detached and died upon serum starvation while untreated cells
remained in stationary state (results not shown).
The defective growth and decreased mtDNA content was also
demonstrated by a decreased BrdU incorporation both in the nucleus
and in the mitochondria, as well as a decrease of staining of the
mitochondrial translation factor TFAM as depicted in a control and in
patient ELN (Fig. 3).
4. Discussion and conclusions
We hereby show that ﬁbroblasts from patients with SUCLA2
deﬁciency have normal amounts of mtDNA, normal NDPK activity,
normal or slightly decreased COX activity, and in one cell line, an
OXPHOS deﬁciency manifesting as decreased growth in galactose
media. Knockdown of SUCLG2 by shRNA in both patient and control
ﬁbroblasts resulted in a signiﬁcant decrease in mtDNA content,
decreased NDPK activity, and a partial decrease in COX activity. Growth
was impaired and most markedly in OXPHOS dependent GAL medium.
The brain and skeletal muscle are the primary organs affected by
SUCLA2 deﬁciency. We have previously hypothesized that the tissue
speciﬁcity is causedby the inability of SUCLG2 to compensate for SUCLA2
deﬁciency as SUCLG2 is only weakly expressed in brain and muscle.
Notably, SUCLG2 is highly expressed in liver and this tissue remains
unaffected in patients with SUCLA2 defects [4,5,18]. We also speculated
that mtDNA depletion in non-dividing tissue in patients with SUCLA2
mutations is caused by disruption of the normal interaction of SUCLA2
with the mitochondrial NDPK, leading to imbalanced mitochondrial
deoxyribonucleotide (dNTP) metabolism [5,19].
Accordingly, we anticipated to ﬁnd near normal or normal mtDNA
content and COX and NDPK activity in patients' cells. The normal
mtDNA/nDNA ratio in the patient cells suggested that SUCLG2 is
indeed able to compensate for the disrupted SUCLA2 in mtDNA
maintenance (Fig. 2A). Nevertheless, the COX activity in patient cells
was partially decreased. This partial impairment of the respiratory
chain was also detected by observing the relative growth impairment
in GAL medium (Fig. 2B and D). Notably, growth in glucose free
medium is highly dependent on oxidative phosphorylation (OXPHOS)
while ATP can be obtained from glycolysis in glucose-containing
medium. The OXPHOS dysfunction seems to be due to an mtDNA-
independent, secondary mechanism. The unaltered NDPK activities in
patient cells also supported this.
Byknocking down the SUCLG2by shRNA inpatient cells,we aimed to
investigate the role of SUCLG2 in compensating for SUCLA2. The severely
decreased mtDNA content, COX activity, and OXPHOS-dependent
growth supports the hypothesis that SUCLG2 can compensate for aSUCLA2 defect. This occurred concomitantly with a signiﬁcant decrease
in NDPK activity, stressing the importance of NDPK in mtDNA
maintenance.
Regretfully, we were not able to accurately measure the amount
NDPK protein due to unsatisfactory signal to noise ratio with different
antibody preparations.
The impairment of growth, especially OXPHOS dependent growth,
in control cells could be attributed to impairment of the Krebs cycle,
suggesting that SUCLG2 is vital in intermediary metabolism and
cannot be replaced by SUCLA2. However, we had not anticipated that
downregulated SUCLG2 in normal cells would show any effect on
mtDNA content or COX and NDPK activities.
The defect in growth andmtDNA content was also clearly visualized
by immunocytochemistry. Notably, in the reciprocal experiment,
SUCLA2 shRNA treated normal cells were not signiﬁcantly different
from the control vector (results not shown).
We conclude and suggest that SUCLG2, to a higher degree than
SUCLA2, is crucial formtDNAmaintenance and thatmitochondrialNDPK
is involved.
Our ﬁndings also conﬁrm the suggested mechanism for tissue
speciﬁcity and the more severe phenotype of some SUCLG1 patients
and may also explain (to our knowledge) the lack of SUCLG2 deﬁcient
patients as such a defect might be incompatible with life.
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